Generate Biomedicines Reports Q3 Results; Cash Runway Extends Into First Half Of 2028; Stock Down
Generate Biomedicines (GENB) reported Q3 2026 results with $4.2M revenue, up from $9.6M in Q3 2025, and a net loss of $87.7M. Cash position is $404.2M, expected to extend into 1H 2028. GB-0895 Phase 3 trials for severe asthma continue. Zealand Pharma collaboration brought $30M upfront. Stock down 6.23%.
